Quick Answer
Contineum Therapeutics, Inc. reported Operating Income of -$68.06 million for fiscal year 2025.
Contineum Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$68.06M | -33.7% |
| 2024 | -$50.89M | -416.6% |
| 2023 | $16.08M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.93M | -15.1% | +16.6% |
| June 30, 2025 | -$17.90M | -63.6% | +1.1% |
| March 31, 2025 | -$18.11M | -82.4% | -39.6% |
| September 30, 2024 | -$12.97M | -60.8% | -18.5% |
| June 30, 2024 | -$10.94M | -128.1% | -10.2% |
| March 31, 2024 | -$9.93M | -94.1% | -23.1% |
| September 30, 2023 | -$8.07M | — | -120.7% |
| June 30, 2023 | $38.94M | — | +861.2% |
- Contineum Therapeutics, Inc. showed a decrease of -33.7% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s operating income has declined by 523.3% (from $16.08 million to -$68.06 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: